BACKGROUND: Enterocyte damage is the hallmark of coeliac disease (CD) resulting in malabsorption. Little is known about the recovery of enterocyte damage and its clinical consequences. Serum intestinal fatty acid binding protein (I-FABP) is a sensitive marker to study enterocyte damage. AIMS: To evaluate the severity of enterocyte damage in adult-onset CD and its course upon a gluten-free diet (GFD). Furthermore, the correlation among enterocyte damage, CD autoantibodies and histological abnormalities during the course of disease is studied. METHODS: Serum I-FABP levels were determined in 96 biopsy-proven adult CD patients and in 69 patients repeatedly upon a GFD. A total of 141 individuals with normal antitissue transglutaminase antibody (IgA-tTG) levels served as controls. I-FABP levels were related to the degree of villous atrophy (Marsh grade) and IgA-tTG. RESULTS: I-FABP levels were elevated in untreated CD (median 691 pg/mL) compared with controls (median 178 pg/mL, P < 0.001) and correlated with Marsh grade (r = 0.265, P < 0.05) and IgA-tTG (r = 0.403, P < 0.01). Upon a GFD serum levels decreased significantly, however, not within the range observed in controls, despite the common observed normalisation of IgA-tTG levels and Marsh grade. CD patients with elevated I-FABP levels nonresponding to GFD showed persistent histological abnormalities. CONCLUSIONS: Enterocyte damage assessed by serum I-FABP correlates with the severity of villous atrophy in coeliac disease at the time of diagnosis. Although enterocyte damage improves upon treatment, substantial enterocyte damage persists despite absence of villous atrophy and low IgA-tTG levels in the majority of cases. Elevated I-FABP levels nonresponding to gluten-free diet are indicative of histological abnormalities and warrant further evaluation.
BACKGROUND: Enterocyte damage is the hallmark of coeliac disease (CD) resulting in malabsorption. Little is known about the recovery of enterocyte damage and its clinical consequences. Serum intestinal fatty acid binding protein (I-FABP) is a sensitive marker to study enterocyte damage. AIMS: To evaluate the severity of enterocyte damage in adult-onset CD and its course upon a gluten-free diet (GFD). Furthermore, the correlation among enterocyte damage, CD autoantibodies and histological abnormalities during the course of disease is studied. METHODS: Serum I-FABP levels were determined in 96 biopsy-proven adult CDpatients and in 69 patients repeatedly upon a GFD. A total of 141 individuals with normal antitissue transglutaminase antibody (IgA-tTG) levels served as controls. I-FABP levels were related to the degree of villous atrophy (Marsh grade) and IgA-tTG. RESULTS:I-FABP levels were elevated in untreated CD (median 691 pg/mL) compared with controls (median 178 pg/mL, P < 0.001) and correlated with Marsh grade (r = 0.265, P < 0.05) and IgA-tTG (r = 0.403, P < 0.01). Upon a GFD serum levels decreased significantly, however, not within the range observed in controls, despite the common observed normalisation of IgA-tTG levels and Marsh grade. CDpatients with elevated I-FABP levels nonresponding to GFD showed persistent histological abnormalities. CONCLUSIONS: Enterocyte damage assessed by serum I-FABP correlates with the severity of villous atrophy in coeliac disease at the time of diagnosis. Although enterocyte damage improves upon treatment, substantial enterocyte damage persists despite absence of villous atrophy and low IgA-tTG levels in the majority of cases. Elevated I-FABP levels nonresponding to gluten-free diet are indicative of histological abnormalities and warrant further evaluation.
Authors: Jocelyn A Silvester; Satya Kurada; Andrea Szwajcer; Ciarán P Kelly; Daniel A Leffler; Donald R Duerksen Journal: Gastroenterology Date: 2017-05-22 Impact factor: 22.682
Authors: Audrey L French; Charlesnika T Evans; Denis M Agniel; Mardge H Cohen; Marion Peters; Alan L Landay; Seema N Desai Journal: J Infect Dis Date: 2013-05-17 Impact factor: 5.226
Authors: Marlou P M Adriaanse; Daniel A Leffler; Ciaran P Kelly; Detlef Schuppan; Robert M Najarian; Jeffrey D Goldsmith; Wim A Buurman; Anita C E Vreugdenhil Journal: Am J Gastroenterol Date: 2016-05-17 Impact factor: 10.864
Authors: Naiomy Deliz Rios-Arce; Fraser L Collins; Jonathan D Schepper; Michael D Steury; Sandi Raehtz; Heather Mallin; Danny T Schoenherr; Narayanan Parameswaran; Laura R McCabe Journal: Adv Exp Med Biol Date: 2017 Impact factor: 2.622
Authors: M Uhde; X Yu; A Bunin; C Brauner; S K Lewis; B Lebwohl; S Krishnareddy; A Alaedini; B Reizis; S Ghosh; P H Green; G Bhagat Journal: Clin Exp Immunol Date: 2020-01-27 Impact factor: 4.330
Authors: Min Gu; Derrick R Samuelson; Christopher M Taylor; Patricia E Molina; Meng Luo; Robert W Siggins; Judd E Shellito; David A Welsh Journal: Alcohol Clin Exp Res Date: 2021-04-03 Impact factor: 3.455